###### Key Points

-   Current peer-reviewed and non--peer-reviewed studies of serologic methods have diverse information. Understanding the strengths and limitations of this literature is critical in the evolution of clinical applications of serologic testing.

-   The use of total antibody or simultaneous IgG/IgM measurements (regardless of method) significantly adds sensitivity to reverse transcription polymerase chain reaction testing protocols early post onset of symptoms and becomes the most accurate diagnostic test at later time points.

-   Additional studies are needed to determine if antibody titers correlate with disease severity and whether certain antigen-specific antibodies determined by routine serologic testing may be surrogate markers for the presence of neutralizing antibodies and long-term immunity.

The first cases of coronavirus disease 2019 (COVID-19) were reported in Wuhan, China, in December 2019.^[@CIT0001]^ As of June 2, 2020, 6,194,533 confirmed cases and 376,320 COVID-19--related deaths have been reported worldwide.^[@CIT0002]^ In the Americas, 2,905,432 cases and 163,248 related deaths were confirmed. The first case of COVID-19 in the United States was reported on January 19, 2020, in Washington.^[@CIT0003]^ Five months later, the United States has become one of the most affected regions with 1,783,638 confirmed cases and 104,247 deaths.^[@CIT0002]^

The rate of transmissibility, environmental stability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the severity of disease in high-risk populations have all contributed to pandemic levels that challenge many health systems. Consequently, understanding and implementing effective evidence-based testing is the cornerstone to correctly identify cases, predict clinical outcomes, and develop treatment strategies. Reverse transcription polymerase chain reaction (RT-PCR) assays used to detect the presence of viral genetic material have become the gold standard of diagnosis. However, RNA extraction techniques, the brief window of RT-PCR sensitivity post symptom onset, and variable levels of viral load have been demonstrated to lead to false-negative results.^[@CIT0004],[@CIT0005]^ Therefore, the implementation of antibody immunoassays is an area of significant interest as an opportunity to increase the accuracy of diagnosis in different scenarios. The current literature describes over 200 immunoassays available worldwide.^[@CIT0004],[@CIT0006]^ Understanding the strengths and pitfalls of these assays in different clinical and research scenarios is critical to move the utilization of serologic testing for SARS-CoV-2 forward.

Materials and Methods {#s1}
=====================

Databases including PubMed, medRxiv, and bioRxiv were searched for published and preprint papers on COVID-19 and coronavirus serology. Search terminology included COVID-19 terms (COVID-19, SARS-CoV-2, novel corona, 2019-ncov) and serology, antibody, neutralizing antibody, seroconversion, rapid testing, IgG, IgM, IgA, LFD, ELISA, PRNT, chemiluminescence, and immunochromatography.

As of June 2, 2020, a total of 55 papers with performance data of serologic techniques were examined. The assays utilized in these studies included the neutralizing antibody assay, enzyme-linked immunosorbent assay (ELISA), automated chemiluminescence immunoassay (CLIA), and lateral flow immunoassay (LFIA). Thirty-two papers were peer-reviewed publications and 23 preprints were not peer-reviewed (medRxiv, 22; bioRxiv, 1).

The compiled information included the assay method with a focus on the detection of particular isotype(s) of antibody and selection of targeted antigen(s). In addition, the composition of cohorts of samples used in the validation studies was examined with focus on control groups. Details regarding the time of sample acquisition and characteristics of the clinical disease of confirmed SARS-CoV-2 patients were also recorded when available. Lastly, calculated test accuracy and information regarding comparison to other immunoassays and RT-PCR testing was noted. Two independent reviewers from the Department of Pathology and Laboratory Medicine and Department of Hematology at the University of Miami and Jackson Health System extracted the information.

Results {#s2}
=======

Overview of Immunoassays {#s3}
------------------------

The SARS-CoV-2 virus is genetically related to the severe acute respiratory syndrome coronavirus (SARS-CoV), which emerged in 2002 to 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV), which was identified in 2012.^[@CIT0001]^ The genomic sequence of SARS-CoV-2 has approximately 82% homology to SARS-CoV and 89% homology with bat SARS-like-CoVZXC21.^[@CIT0001]^

SARS-CoV-2 is a large (50-200 nm) positive-sense single-stranded RNA virus with 4 major structural proteins: nucleocapsid protein (NP) holding the viral RNA and 3 envelope structural proteins including the spike protein (SP), envelope protein (EP), and membrane protein (MP).^[@CIT0012]^ The NP is the most abundant viral protein made and shed during infection. The SP consists of 2 subunits referred to as S1 and S2. S1 contains the receptor-binding domain (RBD) needed for binding to the host angiotensin-converting enzyme 2 (ACE2) receptor.^[@CIT0012]^ S2 contains elements needed for membrane fusion. MP is the most abundant protein on the virion, and EP is the smallest protein and involved in the assembly and release of virions. The SP, RBD, and NP proteins appear to be the main targets of the humoral immune response in coronavirus infections including SARS-CoV-2 and were the antigens used in the majority of the serologic assays examined in this literature review.^[@CIT0012]^

Studies varied widely in the detection of the different isotypes of antibody: IgM, IgA, and IgG. Many immunoassays, referred to as total antibody assays, were constructed to detect levels of all isotypes simultaneously. While a few studies presented quantitative data, the large volume of current literature described mostly qualitative and semiquantitative immunoassays.

In the analysis of these studies, it is essential to examine the details of sample size and the patient population(s).^[@CIT0015],[@CIT0016]^ The design of a comprehensive validation study to address assay specificity requires the assessment of 3 groups of samples: confirmed SARS-CoV-2 infected patients, confirmed healthy negative controls, and secondary sets of controls from patients with other viral infections and diseases. The latter group should include samples from patients with other human coronavirus infections. For sensitivity data, consideration of the timing of sample acquisition related to the onset of symptoms is crucial. Samples acquired at very early times may represent a period where antibody levels are not present or are below the level of detection. Finally, the performance of the assays will be affected by the technical component of the assays themselves. For LFIA, reactivity is determined by visual inspection of bands on the immunochromatography paper present in single use devices. In the case of the semiautomated ELISA and automated CLIA methods, the quantitation is provided by spectrometry and luminescence detection, respectively.

It is important to note that many non--peer-reviewed manuscripts were included in this review; the reader is advised to search for final refereed versions that may have updated data and discussion points.

### Lateral Flow Immunoassay (LFIA) {#s4}

The variable sensitivity and specificity of LFIA have been the focus of the media and numerous studies due to the growing number of commercially available devices.^[@CIT0006],[@CIT0017]^ Several investigations reported high sensitivity and specificity of these assays although many lacked information regarding the target antigens and well-defined negative control groups (ie, human coronavirus controls). **[Table 1](#T1){ref-type="table"}** summarizes the review of studies using LFIA methods.^[@CIT0006],[@CIT0007],[@CIT0018]^

###### 

Studies Reporting the Use of Lateral Flow Immunoassay Methods in the Detection of Antibody to SARS-CoV-2

  Antigen    No. of Positive Patient Samples^a^   No. of Negative Patient Samples^b^   No. of Other Samples^c^   Sensitivity, Specificity (%)                     Comments                                                                Reagent Manufacturer                                                                            Reference
  ---------- ------------------------------------ ------------------------------------ ------------------------- ------------------------------------------------ ----------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- -----------------------------------
  RBD        397                                  128                                  ND                        89, 91                                           IgM, IgG                                                                BioMedomics                                                                                     Li et al^[@CIT0007]^
  Unk        30                                   Unk                                  Unk                       83-93, 100                                       Variable performance, 32 samples used in specificity were not defined   Acro Biotech, Arton Labs, Autobio, CTK Biotech, Dynamiker, Hangzhou Alltest Biotech             Lassaunière et al^[@CIT0018]^
  Unk        91                                   35                                   ND                        82, 100                                          IgM, IgG                                                                Zhuhai Livzon Diagnostics                                                                       Xiang et al^[@CIT0019]^
  NP         109^d^                               60                                   14                        77, 100                                          IgM                                                                     Zhuhai Livzon Diagnostics                                                                       Xiang et al^[@CIT0020]^
  NP         109^d^                               60                                   14                        83, 95                                           IgG                                                                     Zhuhai Livzon Diagnostics                                                                       Xiang et al^[@CIT0037]^
  Unk        191^d^                               ND                                   ND                        30, 89                                           IgM, IgG; PCR+ vs PCR--                                                 Viva-Chek                                                                                       Paradiso et al^[@CIT0021]^
  NP         80                                   209                                  ND                        86, 100                                          IgG                                                                     Wantai                                                                                          Lou et al^[@CIT0022]^
  RBD        80                                   209                                  ND                        89, 98                                           IgM                                                                     Wantai                                                                                          
  RBD        80                                   209                                  ND                        98, 95                                           Total antibody                                                          Wantai                                                                                          
  Unk        90                                   ND                                   64^e^                     85,91                                            IgM, IgG; timeline, severity                                            Unknown                                                                                         Liu et al^[@CIT0023]^
  Unk        86                                   ND                                   ND                        Sensitivity only: 11 (\<7 d), \>90 after day 8   IgM, IgG; timeline                                                      Zhuhai Livzon Diagnostics                                                                       Pan et al^[@CIT0024]^
  Unk        76                                   ND                                   ND                        Sensitivity only: IgM 50%, IgG 92%               Examined serology vs PCR in timeline post symptom onset                 Beijing Innovita Biological Technology                                                          Yong et al^[@CIT0025]^
  SP + NP    93                                   ND                                   9-44                      87-89, 81-100                                    IgM, 2 devices examined                                                 Cellex, Orient Gene                                                                             Geurtsvankessel et al^[@CIT0026]^
  SP + NP    93                                   ND                                   9-44                      84-92, 85-100                                    IgG, 2 devices examined                                                 Cellex, Orient Gene                                                                             
  NP         93                                   ND                                   64                        88, 74                                           IgM                                                                     Intec                                                                                           
  NP         93                                   ND                                   64                        95,77                                            IgG                                                                     Intec                                                                                           
  Unk        128                                  72                                   ND                        69-72, 96-100                                    IgM, IgG, 3 devices                                                     LabOn Time, Avioq, QuickZen                                                                     Montesinos et al^[@CIT0027]^
  Multiple   77                                   60                                   40                        Specificity 98-100                               IgM, IgG timeline for sensitivity                                       Wantai, Hangzhou All Biotech                                                                    Traugott et al^[@CIT0028]^
  Multiple   167                                  ND                                   103                       Specificity 97-100                               IgM, IgG timeline for sensitivity                                       Clungene, OrientGene, VivaDiag, StrongStep, Dynamiker, Multi-G, Prim                            Van Elslande et al^[@CIT0029]^
  Multiple   130                                  108                                  52                        81-100, 84-100                                   IgM, IgG timeline                                                       BioMedomics, Bioperfectus, DecomBio, DeepBlue, Innovita, Premier, Sure, UCP, VivaChek, Wondfo   Whitman et al^[@CIT0006]^

ND, not done; NP, nucleocapsid protein; RBD, receptor-binding domain; RT-PCR, reverse transcription polymerase chain reaction; SP, spike protein; Unk, unknown.

^a^Positive RT-PCR results for SARS-CoV-2.

^b^Healthy controls.

^c^Inclusion of banked samples from patients with other viral infections including other human coronaviruses.

^d^Cohort included some samples from probable COVID-19 patients based on clinical presentation and other test results.

^e^Inclusion of samples from patients with autoimmune diseases.

The experimental design and data of 7 studies were judged to provide insight into LFIA method applications. Li et al^[@CIT0007]^ evaluated a combined IgM/IgG LFIA using the RBD antigen in a sample set obtained from 397 positive patients defined by positive RT-PCR and COVID-19 symptoms and 128 negative patients. The assay sensitivity was 89% and the specificity was 91%. Notably, 64% of the samples from the positive patient group demonstrated both IgM and IgG reactivity. Lou et al^[@CIT0022]^ reported the use of 3 different LFIA: IgM and total antibody using RBD antigen and IgG detection using NP antigen. Using a large group of COVID-19--negative patient samples (n = 209) but not a control group of samples from patients with other viral infections or diseases, an excellent specificity ranging from 95% to 100% was reported for all 3 devices. Notably, the sensitivity of the total antibody LFIA had the highest performance at 98%. Also, the performance of all the assays compared well with similarly constructed and validated ELISA in the same study. Using 147 control samples from patients with various viral infections and 93 samples from COVID-19 patients, Geurtsvankessel et al^[@CIT0026]^ reviewed 3 LFIA including the Cellex. This device uses a combination of SP and NP antigens. The sensitivity and specificity were calculated as 87% and 81% for IgM detection and 84% and 85% for IgG detection, respectively. Interestingly, the Orient LFIA, also constructed with the same 2 antigens, showed a sensitivity of 89% for IgM detection and 92% for IgG detection. The assay specificity for each isotype was 100%, but it should be noted that the latter study tested a very small sample set of negative controls. Another study utilized samples from both negative patients and patients with other viral infections and examined 6 LFIA devices.^[@CIT0018]^ Although no target antigen information was presented, the patient sample sets were robust. While evaluation of 2 of the LFIA demonstrated a poor performance, the remaining devices demonstrated 83% to 93% sensitivity and 100% specificity values. Lastly, Traugott et al^[@CIT0028]^ presented data regarding 2 LFIA with specificity ranging from 98% 100%, but sensitivity was reported as poor at less than 5 days post onset of symptoms (13%-20%), poor to moderate at days 6 to 10 (20%-80%), and excellent at or after day 11 (100%).

One study examined the accuracy of 10 different LFIA and 2 ELISA immunoassays using samples obtained from COVID-19 patients at different time points of disease.^[@CIT0006]^ Specificity was assessed using 108 samples from healthy subjects and 52 samples from patients with other respiratory illnesses (not specified). The highest detection rate observed using LFIA devices was obtained with combined IgM and IgG detection. Accuracy peaked at days 16 to 20 post onset of symptoms with sensitivity results greater than 80% and specificity results greater than 95%. Notably, this study reported several false-positive results obtained from banked specimens collected before the pandemic. These false-positive results suggest nonspecific binding by plasma proteins or cross-reactivity with antibodies produced during other viral infections. In a separate study of 7 LFIA devices, Van Elslande et al^[@CIT0029]^ also used a secondary set of 103 control samples to assess assay performance and reported a range of 97% to 100% specificity with the combination of positive IgM and IgG results but an 85% to 98% range of specificity when only IgM or IgG positive results were used. In their study, sensitivity was also reported to vary with the timing of sample acquisition post onset of symptoms.

LFIA is an appealing platform for SARS-CoV-2 testing with a relatively low cost per test and the advantage of potential use for point-of-care testing.^[@CIT0030]^ LFIA described in the literature thus far provided results for both IgM and IgG. The majority of the reports demonstrated a higher sensitivity and specificity with the detection of both isotypes, and a higher specificity was observed with the detection of the IgG isotype over the detection of the IgM isotype alone. Antigens frequently used in LFIA include NP, RBD, and combined use of NP and SP. A superior test accuracy based on the use of specific target antigen(s) was not evident at this time. Studies utilizing samples obtained at various time points demonstrated the accuracy of LFIA was optimal at approximately 2 weeks post onset of symptoms. Overall, the understanding of the limitations or advantages for the implementation of LFIA-based assays is severely impacted by the presence of only a few properly designed studies in the current literature ([Table 1](#T1){ref-type="table"}).

### Enzyme-Linked Immunosorbent Assay (ELISA) {#s5}

Publications that described ELISA method validation often sought to address which antigens and antibody isotypes provided the best sensitivity and specificity **[Table 2](#T2){ref-type="table"}**.^[@CIT0006],[@CIT0018],[@CIT0019],[@CIT0022],[@CIT0026],[@CIT0031]^ In many of these studies, these calculations were reported solely to compare the performance of different antigens or the detection of different isotypes and not necessarily to propose the use of the assay for clinical implementation. Additionally, as noted in [Table 2](#T2){ref-type="table"}, many investigations utilized the ELISA method to study the timeline of antibody expression in SARS-CoV-2 patients.

###### 

Studies Reporting the Use of Enzyme-Linked Immunosorbent Assay Methods in the Detection of Antibody to SARS-CoV-2

  Antigen           No. of Positive Patient Samples^a^   No. of Negative Patient Samples^b^   No. of Other Samples^c^   Sensitivity, Specificity (%)           Comments                                                           Reagent Manufacturer                      Reference
  ----------------- ------------------------------------ ------------------------------------ ------------------------- -------------------------------------- ------------------------------------------------------------------ ----------------------------------------- -----------------------------------
  SP, RBD           16                                   0                                    50                        ND                                     Also isotype expression                                            Lab-developed test                        Amanat et al^[@CIT0031]^
  RBD               30                                   10                                   72                        93, 100                                Total antibody                                                     Wantai                                    Lassaunière et al^[@CIT0018]^
  S1                30                                   10                                   72                        67, 96                                 IgG                                                                Euroimmun                                 
  S1                30                                   10                                   72                        93, 93                                 IgA                                                                Euroimmun                                 
  NP                208^d^                               150                                  140                       ND                                     IgM, IgG, IgA timeline                                             Lab-developed test                        Guo et al^[@CIT0032]^
  RBD               161                                  213                                  ND                        93, 99                                 Total antibody timeline                                            Lab-developed test                        Zhao et al^[@CIT0033]^
  RBD               143                                  213                                  ND                        83, 99                                 IgM timeline                                                       Lab-developed test                        
  NP                112                                  197                                  ND                        65, 99                                 IgG timeline                                                       Lab-developed test                        
  SP, S1, NP, RBD   41                                   76                                   192                       ND^e^                                  IgG and IgA, PRNT                                                  Euroimmun and lab-developed tests         Okba et al^[@CIT0034]^
  NP                214                                  100                                  ND                        80, 100                                IgM, IgG timeline                                                  Lizhu                                     Liu et al^[@CIT0035]^
  RBD               214                                  100                                  ND                        82, 100                                IgM, IgG timeline                                                  Hotgen                                    
  NP                80                                   100                                  ND                        89, 100                                IgG                                                                Wantai                                    Lou et al^[@CIT0022]^
  RBD               80                                   300                                  ND                        98, 100                                Total antibody                                                     Wantai                                    
  RBD               80                                   300                                  ND                        93, 100                                IgM                                                                Wantai                                    
  NP                238                                  120                                  ND                        82, 94                                 vs PCR results, timeline                                           Lizhu                                     Liu et al^[@CIT0036]^
  NP + RBD          12                                   6                                    ND                        ND                                     Also quantitative titers                                           Lab-developed test                        Ni et al^[@CIT0037]^
  NP                16                                   ND                                   ND                        Sensitivity: 94 IgG, 88 IgM            IgM, IgG                                                           Lab-developed test                        To et al^[@CIT0038]^
  RBD               16                                   ND                                   ND                        Sensitivity: 100 IgG, 94 IgM                                                                              Lab-developed test                        
  Unknown           63                                   35                                   ND                        87, 100                                Compared to LFIA                                                   Zhuhai Livzon Diagnostics                 Xiang et al^[@CIT0019]^
  RBD               76                                   ND                                   150                       99, 99                                 Total antibody                                                     Wantai                                    Geurtsvankessel et al^[@CIT0026]^
  RBD               76                                   ND                                   150                       89, 99                                 IgM                                                                Wantai                                    
  S1                43                                   ND                                   161                       82, 99                                 IgG                                                                Euroimmun                                 
  S1                76                                   ND                                   161                       97, 94                                 IgA                                                                Euroimmun                                 
  S1, RBD           77                                   60                                   40                        Specificity 83 (IgA), 97-98 (others)   IgA, IgG, IgM, total antibody; sensitivity presented by timeline   Euroimmun, Wantai                         Traugott et al^[@CIT0028]^
  RBD               130                                  108                                  52                        \>80, \>95                             IgM/IgG 16 d after symptoms                                        Epitope Diagnostics, lab-developed test   Whitman et al^[@CIT0006]^
  S1                128                                  10                                   72                        84, 88                                 IgG, IgA, timeline                                                 Euroimmun                                 Montesinos et al^[@CIT0027]^
  S1                69                                   412                                  ND                        97, 98                                 Also asymptomatic study                                            Lab-developed test                        Zhao et al^[@CIT0039]^
  SP, NP            130                                  16                                   ND                        ND                                     IgG and prognosis                                                  Lab-developed test                        Sun et al^[@CIT0040]^

LFIA, lateral flow immunoassay; ND, not done; NP, nucleocapsid protein; PRNT, plaque reduction neutralization test; RBD, receptor-binding domain; RT-PCR, reverse transcription polymerase chain reaction; SP, spike protein.

^a^Positive RT-PCR results for SARS CoV-2.

^b^Healthy controls.

^c^Inclusion of banked samples from patient with other viral infections including other human coronaviruses.

^d^Cohort included some samples from probable COVID-19 patients based on clinical presentation and other test results.

^e^Addressed in study but no formal calculations.

To date, few investigations have focused on immunoassays utilizing the full SP antigen.^[@CIT0031],[@CIT0034]^ The SP antigen includes the RBD antigen as well as other essential peptides that may be the target of the humoral immune response. Amanat et al^[@CIT0031]^ generated 2 different versions of the SARS-CoV-2 spike protein. One construct expressed the full length of SP and a second construct presented only the RBD. Evaluating a small number of samples from RT-PCR--positive patients, reactivity to both antigens was excellent as demonstrated by optical density values. However, SP reactivity was significantly higher than that observed for RBD. IgG3, IgM, and IgA were the dominant isotypes observed in these patient samples. The investigators further reported that reactivity to a sample bank of sera obtained from patients with other human coronavirus infections was negligible.

Okba et al^[@CIT0034]^ produced an array of different ELISA to examine antibody reactivity to SP, S1, NP, and RBD antigens. A large cohort of samples was obtained from patients with other viral respiratory infections and was inclusive of 116 banked samples from patients infected with various human coronaviruses. Only samples from some SARS-CoV and MERS-CoV patients cross-reacted with the SARS-CoV-2 antigens. The RBD and NP ELISA were the most effective in the detection of antibodies in patients with mild infection. These 2 antigens were examined in a second study using samples obtained from a cohort of 16 patients obtained 14 days or longer after symptom onset.^[@CIT0038]^ The RBD ELISA showed higher sensitivity (100% for IgG and 94% for IgM) compared to the NP ELISA (94% for IgG and 88% for IgM).

Okba et al^[@CIT0034]^ also examined commercial ELISA using the S1 antigen for the detection of IgA and IgG antibodies. Both ELISA showed some cross-reactivity with samples obtained from other human coronavirus positive patients. Overall, the IgA ELISA displayed a higher sensitivity and the IgG ELISA displayed a higher specificity.

Lassaunière et al^[@CIT0018]^ evaluated ELISA constructed with RBD and S1 antigens using a control group of samples from patients with other non--SARS-CoV-2 viral infections. The performance of a sandwich ELISA for the detection of total antibody reactivity to RBD was superior to that observed for the commercial IgG and IgA ELISA using the S1 antigen. The ELISA for total antibody detection provided the highest sensitivity and specificity of 93% and 100%, respectively. The specificity of the IgG and IgA assays were similar, but the IgA ELISA had a superior sensitivity of 93% vs 67% for IgG. The authors reported a similar cross-reactivity of the commercial S1 ELISA to other human coronaviruses as observed by Okba et al.^[@CIT0034]^

Zhao et al^[@CIT0033]^ also utilized a sandwich ELISA to measure total antibody reactivity to RBD antigen as well as a RBD targeted ELISA to measure IgM reactivity alone and a NP targeted ELISA to detect IgG reactivity. Examining a cohort of over 300 patient samples, the total antibody assay had superior performance vs the other assays with a sensitivity and specificity of 93% and 99%, respectively. While the specificity of the IgM and IgG ELISA was 99%, the sensitivity of the IgG ELISA (NP) was 65% compared to the IgM ELISA (RBD) at 83%.

Whitman et al^[@CIT0006]^ evaluated 2 different ELISA and 10 different LFIA. In their study, the sensitivity for the ELISA assays using samples obtained after day 16 post onset of symptoms was greater than 80% and the specificity was greater than 95%. The agreement of the ELISA with different LFIA ranged from 75 to 95%.

Overall, ELISA assays with RBD and NP antigens were the most frequently used in these early studies. Although the sensitivity of the assays was affected by the timing of sample acquisition, a higher overall sensitivity was consistently observed with the use of total antibody detection. The ELISA technique is labor intensive and unsuitable for point-of-care testing; however, it may offer the advantage of determining antibody titers and selective isotype detection. The importance of these options as clinical applications is unknown at this time. Overall, while several ELISA-based studies were robust in experimental design, many reports did not include examination of important control samples to best evaluate method specificity ([Table 2](#T2){ref-type="table"}).

### Direct Chemiluminescence Immunoassay (CLIA) {#s6}

The use of CLIA in the detection of SARS-CoV-2 antibody is of particular interest, as this method has excellent sensitivity with a high signal-to-noise ratio in the detection of other viral infections. CLIA uses recombinant antigen coated magnetic beads and a lumigen substrate with analysis on automated platforms. In current reports, NP, combined NP and SP, and RBD antigens were most commonly used **[Table 3](#T3){ref-type="table"}**.^[@CIT0008],[@CIT0022],[@CIT0026],[@CIT0027],[@CIT0041]^

###### 

Studies Reporting the Use of Chemiluminescence Immunoassay Methods in the Detection of Antibody to SARS-CoV-2

  Antigen   No. of Positive Patient Samples^a^   No. of Negative Patient Samples^b^   No. of Other Samples^c^   Sensitivity, Specificity (%)   Comments                Reagent Manufacturer                     Reference
  --------- ------------------------------------ ------------------------------------ ------------------------- ------------------------------ ----------------------- ---------------------------------------- -----------------------------------
  NP + SP   228                                  225                                  222                       ND                             IgM and IgG             Shenzhen YHLO Biotech                    Zhang et al^[@CIT0041]^
  NP + SP   363^d^                               ND                                   ND                        ND                             IgM and IgG             Bioscience                               Long et al^[@CIT0042]^
  NP        79                                   29                                   51                        82, 81                         IgM                     Lab-developed test                       Lin et al^[@CIT0043]^
  NP        79                                   29                                   51                        82, 97                         IgG                     Lab-developed test                       
  NP + SP   43                                   33                                   ND                        48, 100                        IgM                     Shenzhen YHLO Biotech                    Jin et al^[@CIT0008]^
  NP + SP   43                                   33                                   ND                        89, 91                         IgG                     Shenzhen YHLO Biotech                    
  RBD       80                                   300                                  ND                        96, 99                         Total antibody          Xiamen InnoDx Biotech                    Lou et al^[@CIT0022]^
  RBD       80                                   300                                  ND                        86, 99                         IgM                     Xiamen InnoDx Biotech                    
  RBD       216                                  330                                  153                       97, 100                        IgG                     Lab-developed test                       Ma et al^[@CIT0044]^
  NP        216                                  ND                                   20                        96, 100                        IgG                     Lab-developed test                       
  RBD       216                                  330                                  153                       97, 92                         IgM                     Lab-developed test                       
  NP        216                                  ND                                   20                        78, 95                         IgM                     Lab-developed test                       
  RBD       216                                  330                                  153                       99, 98                         IgA                     Lab-developed test                       
  NP        216                                  ND                                   20                        90, 85                         IgA                     Lab-developed test                       
  S1/S2     53                                   ND                                   69                        74, 99                         Total antibody          DiaSorin                                 Geurtsvankessel et al^[@CIT0026]^
  NP + SP   54                                   180                                  55                        100, 99                        IgM and IgG at day 15   Diazyme                                  Suhandynata et al^[@CIT0045]^
  Unknown   122                                  10                                   72                        64, 100                        IgM and IgG             Maglumi                                  Montesinos et al^[@CIT0027]^
  NP        689                                  ND                                   1,020                     53-100, 100                    IgG                     Abbott, sensitivity examined over time   Bryan et al^[@CIT0046]^

ND, not done; NP, nucleocapsid protein; RBD, receptor-binding domain; SP, spike protein.

^a^Positive RT-PCR results for SARS CoV-2.

^b^Healthy controls.

^c^Inclusion of banked samples from patient with other viral infections including other human coronaviruses.

^d^Cohort included some samples from probable COVID-19 patients based on clinical presentation and other test results.

Many studies utilized CLIA to address differences in patient populations and time of onset of symptoms vs serologic results. Long et al^[@CIT0042]^ reported the use of the NP and SP antigen combination in a study of 363 samples from confirmed and suspect COVID-19 patients. In their report, IgG-positive serostatus approached 100% at 20 days after onset of symptoms, and the median seroconversion for IgM and IgG was 13 days. Using a similar NP and SP assay but a smaller cohort of positive and negative patients, Jin et al^[@CIT0008]^ reported a 48% sensitivity and 100% specificity for IgM detection. However, for IgG, the reported sensitivity was 89% and specificity was 91%. Accuracy was higher for combined IgM and IgG testing with a posterior probability of greater than 99%; this was followed by IgG alone (90%) and IgM alone (86%) and was corroborated in a separate study.^[@CIT0047]^

Five studies warranted a closer examination, as each included control samples from patients with non-SARS-CoV-2 infections. Lin et al^[@CIT0043]^ used NP antigen to detect IgM and IgG reactivity. Sensitivity for both IgM and IgG assays was reported as 82%, and the specificity was 81% for IgM detection and 98% for IgG detection. Ma et al^[@CIT0044]^ compared RBD and NP antigen targeted CLIA and reported a higher sensitivity and specificity when using the RBD antigen. A superior sensitivity and specificity were also demonstrated with the detection of IgA over IgM or IgG detection alone. In addition, the use of IgA in tandem with the detection of either IgM or IgG increased assay sensitivity and specificity. Geurtsvankessel et al^[@CIT0026]^ examined a total antibody assay for S1/S2 reactivity and reported a sensitivity of 73% and a specificity of 98%. Bryan et al^[@CIT0046]^ validated an IgG antibody assay using NP antigen with a specificity of 100% based on the analysis of banked samples originally submitted for HSV testing. This study also included 689 samples from confirmed COVID-19 patients. The assay sensitivity increased from 53% at day 7 to 100% at day 17. Lastly, Zhang et al^[@CIT0041]^ used a large cohort of samples and showed an area under the curve of 0.99 and 1.00 for IgM and IgG, respectively, using a combined NP and SP CLIA.

The CLIA assay is traditionally considered a very sensitive method with the capability to detect low levels of antibodies. CLIA assays are automated and allow for a high throughput of samples. In the current literature review, RBD and NP were the most commonly targeted antigens, and the studies detected IgM and IgG isotypes as well as total antibody reactivity. The use of RBD antigen and IgG detection produced the highest accuracy data among studies. It is important to consider that the variation in performance among different platforms may have been related to sample acquisition timing, which was not consistently reported in the studies.

Practical Implementation of Serologic Testing {#s7}
---------------------------------------------

### Diagnosis in Symptomatic Patients {#s8}

RT-PCR testing for viral detection is a frontline tool to detect patients with suspected SARS-CoV-2 infection. However, several studies showed that the sensitivity of RT-PCR testing decreased over time post onset of symptoms and that this change was observed to be concurrent with the increasing sensitivity of antibody detection methods.

Guo et al^[@CIT0032]^ evaluated the use of a NP targeted ELISA using IgM, IgA, and IgG detection in a sample set of 82 RT-PCR confirmed cases and 58 suspected cases with negative RT-PCR. Early in disease (5 days post onset of symptoms), IgM detection was positive in 93% of suspected cases with negative RT-PCR results and 76% of the RT-PCR confirmed cases. Overall, the sensitivity of RT-PCR testing alone was 52%; however, when using RT-PCR in combination with the ELISA, the total sensitivity increased to 99%. Similar results were observed in another study where combined detection of IgG and IgM identified over 70% of suspected cases that were negative by RT-PCR testing.^[@CIT0038]^

As the course of the disease progresses, the utility of serology increases as well. Zhao et al^[@CIT0033]^ evaluated the sensitivity of a total antibody ELISA to the RBD antigen. In the early (1-7) days post onset of symptoms, the sensitivity was 67% for RT-PCR; this increased to 79% when RT-PCR was combined with ELISA testing. The sensitivity for RT-PCR decreased to 54% at days 8 to 14 while the ELISA sensitivity increased to 90%. At this time point, the use of both methods resulted in a sensitivity of 97%. Lastly, on days 15 to 39, RT-PCR sensitivity was reported as 46%, and the ELISA sensitivity was 100%. Similar trends were also observed with an IgM RBD ELISA and IgG NP ELISA.

### Serology Use in Monitoring Disease Course {#s9}

Numerous studies indicated that antibody responses may vary according to disease severity, and some reports proposed that monitoring titers may be applied in clinical practice to guide earlier aggressive treatment. Traditionally, the hallmarks of a humoral immune response include the early expression of IgM isotype, which then matures into IgG isotype expression. Notably, many reports of SARS-CoV-2 patients indicated that IgM expression was observed concurrently with IgG expression. Long et al^[@CIT0042]^ conducted a large multicenter study using an NP and SP targeted CLIA. The median seroconversion of both isotypes was recorded at day 13. In addition, a different NP and SP targeted CLIA studied by Suhandynanata et al^[@CIT0045]^ showed a median seroconversion on days 4 to 5 for IgM and IgG.

The goal of several ELISA studies was to define the period of seroconversion, and all demonstrated the higher sensitivity of the assays by the second week post onset of symptoms.^[@CIT0020],[@CIT0028],[@CIT0032],[@CIT0033]^ Zhao et al^[@CIT0033]^ reported that the median seroconversion time of IgM and IgG to RBD antigen was days 12 and 14, respectively. Guo et al^[@CIT0032]^ reported the median appearance of IgM and IgA at day 5 and IgG at day 14 post symptom onset. Their study used serial samples obtained from the same patients and an ELISA for antibody detection to the NP antigen. Xiang et al^[@CIT0020]^ also used a NP targeted ELISA and reported the median appearance of antibody at day 4 post onset of symptoms. Overall, while these results are similar to that reported in a review of serologic testing for MERS-CoV and SARS-CoV, they may have been affected by choice of target antigens, the various immunoassay kits, and the level of detail of case history used to categorize the time of sample acquisition post onset of symptoms.^[@CIT0014]^

Few studies have examined the differences in titers by case severity classification, and there was no consensus among the findings. Tan et al^[@CIT0049]^ reported that the IgG and IgM detection occurred earlier for severe cases compared to nonsevere cases (*P* \< .05). Higher titers were also observed in the former group. Wang et al^[@CIT0050]^ evaluated the titers of IgM and IgG in 116 confirmed cases of which 101 of the cases had mild to moderate disease and 15 patients died. Levels of IgM were significantly higher in deceased patients (*P* = .019). However, no significant correlation was observed between case outcome and IgG titers. In contrast, a large study of 338 confirmed COVID-19 patients reported elevated IgM titers but lower IgG levels in critical cases.^[@CIT0051]^ Ma et al^[@CIT0044]^ evaluated IgA titers in a cohort of 216 patients and observed a significant correlation with disease severity (*P* \< .0001) and peak levels of IgA 16 to 20 days after symptom onset. Sun et al^[@CIT0040]^ reported significantly higher IgG titers to SP antigen in non-ICU patients, whereas IgG titers to NP antigen were elevated in ICU patients. Lastly, To et al,^[@CIT0038]^ using NP and RBD targeted ELISA observed no correlation between titers and severity.

Previously, quantification performed by ELISA and neutralizing antibody assays showed that individuals over 60 years of age had higher antibody titers than young healthy adults with human coronavirus (non--SARS-CoV-2) infection.^[@CIT0052]^ Notably, in a study of patients recovered from COVID-19, samples obtained from elderly and middle-aged individuals had higher titers of SP reactive antibody compared to young adults.^[@CIT0053]^ Thus, while increased age is often associated with severe SARS-CoV-2 disease and poor outcomes, high levels of antibody production do not appear to be detrimental given these preliminary reports.

### Serology Use for Screening Asymptomatic Patients {#s10}

There were limited reports of testing approaches for the detection of asymptomatic individuals. Much of the current literature was weakened given the limitations in the experimental design of studies used to validate the serologic methods. For example, Paradiso et al^[@CIT0054]^ used an LFIA for IgM and IgG detection to screen 525 health care workers. Previously, this group reported an overall 30% sensitivity and 89% specificity obtained during the validation of this LFIA. It was acknowledged that the reduced sensitivity was related to the selection of validation samples from patients early after the onset of symptoms.^[@CIT0021]^ In the health care worker screening study, only 1.1% of the cases were seropositive; these cases tested negative by RT-PCR. All the cases were positive for IgM, and 1 case was positive for both IgM and IgG. Another study from the same investigation group examined asymptomatic cases presenting to the emergency department.^[@CIT0021]^ Twenty nine percent of the cases were positive by RT-PCR testing and 21% of the cases were positive by LFIA testing. As the LFIA was not fully validated, it is problematic to apply these results to develop screening strategies for asymptomatic patients.

Bendavid et al^[@CIT0055]^ used LFIA in a study of 3,330 individuals from Santa Clara County, CA, and found an unadjusted antibody prevalence of 1.5% (95% confidence interval \[CI\], 1.11%-1.97%). The weighted population prevalence was 2.8% (95% CI, 2.24%-3.37%).^[@CIT0055]^ The kit was validated using samples from confirmed negative and positive SARS-CoV-2 patients with a combined IgM/IgG sensitivity of 80% and specificity of 99%. No secondary controls with non--SARS-CoV-2 viral infections were included in the validation study. As a result, this study likely overestimated the specificity of this LFIA.

Zhao et al^[@CIT0039]^ used a lab-developed ELISA for the detection of IgG antibody to S1 antigen with reported excellent sensitivity and specificity, as determined by the use of samples from symptomatic hospitalized patients and healthy individuals. In a subsequent study, the same ELISA was examined in 276 asymptomatic health care workers. Ten percent of health care workers had seropositive results. Samples from a small cohort of close contact individuals were also examined. All subjects tested negative by RT-PCR, but 1 individual was seropositive. As with the study by Bendavid et al,^[@CIT0055]^ the specificity of the ELISA assay was not fully assessed; this complicates the interpretation of these results.

A report of serologic testing of a family cluster of 6 individuals provided interesting data regarding the complexity of test sensitivity.^[@CIT0056]^ Two family members were hospitalized with SARS-CoV-2 symptoms. One individual tested positive by RT-PCR on presentation, and the second patient tested negative twice before obtaining a positive result on day 5. Both individuals were positive for IgM reactivity by ELISA. The 4 remaining family members remained asymptomatic. However, 3 of 4 tested positive for IgM reactivity, and 2 of 3 were positive by RT-PCR testing at later dates. The fourth individual remained clinically asymptomatic and was negative on all testing.

Implementation of serology testing to screen the general population and asymptomatic health care workers is currently of significant interest. Nonetheless, the available evidence is limited to support its use in these scenarios. With unclear population prevalence and the use of immunoassays that are not fully validated, the limitations of test sensitivity and specificity in the evaluation of asymptomatic individuals may be difficult to overcome.^[@CIT0057]^

### Utility for Possible Convalescent Serum Donors {#s11}

Many studies focused on the detection of neutralizing antibodies for the potential use as a predictor of clinical outcome and in the identification of convalescent serum for use in a treatment strategy. Several of these studies evaluated the correlation of data from ELISA using RBD, S1, S2, and NP antigens to the presence of neutralizing antibodies. Wu et al^[@CIT0053]^ studied neutralizing antibodies using a pseudotyped-lentiviral-vector-based assay using plasmids for SARS-CoV and SARS-CoV-2 SP protein. Titers of neutralizing antibodies were reported as ID50 (highest dilution resulting in 50% reduction of luciferase luminescence). Parallel ELISA for SARS-CoV and SARS-CoV-2 RBD, S1, and S2 were conducted. The study samples were obtained from 175 patients with mild to moderate symptoms who recovered from COVID-19. Levels of neutralizing antibodies were low (ID50, \<200) before day 10 and appeared at 10 to 15 days after the onset of symptoms. Titers persisted at similar levels on repeat testing 2 weeks later. The levels of neutralizing antibodies in the patients were categorized as follows: low to mid in 17% (ID50, 500-999), mid to high 39% (ID50, 1,000-2,500), and high in 14% (ID50, \>2,500). Samples from 30% of patients had very low levels (ID50, \<500) and included samples from 10 patients who had reactivity below the level of detection (ID50, \<40). Results obtained from ELISA using RBD, S1, and S2 antigens correlated moderately with neutralizing antibody titers. Correlation coefficients ranged from 0.42 to 0.51 (*P* \< .0001). Ni et al^[@CIT0037]^ examined RBD and NP ELISA in tandem with the pseudovirus neutralization test in cohorts of 6 patients tested at the time of discharge and 2 weeks later. Significant levels of IgM and IgG were present at both time points as determined by ELISA methods. Notably, while neutralizing antibody was detected at the time of discharge, levels were lower in 5 of 6 patients 2 weeks later.

Okba et al^[@CIT0034]^ compared the results of IgA and IgG ELISA for RBD, S1, and NP to data obtained from a plaque reduction neutralization assay (using Vero E6 cells) and reported a significant correlation (*r* = 0.88, *P* \< .01) with all ELISA. The strongest correlation was observed with IgA reactivity (*r* = 0.93, *P* \< .001). It is important to note that various ELISA in this study were validated with a large secondary sample set obtained from patients with other respiratory viral infections ([Table 2](#T2){ref-type="table"}).

The identification of novel antigenic epitopes that may be important in the humoral immune response was the focus of a limited number of studies. Poh et al^[@CIT0013]^ evaluated the reactivity of 25 convalescent serum samples. Six samples showed significant neutralization activity (ID50, \>600) and were selected for further analysis. Additional experiments to characterize antigen targets showed that the S14 and S21 peptides (within the SP) provided the strongest reactivity by ELISA methods, and these results correlated with neutralizing activity. Jiang at al^[@CIT0058]^ developed a microarray of 28 SARS-CoV-2 proteins to profile IgG/IgM responses of 29 convalescent sera. All patients had combined IgM/IgG responses to NP and S1 antigens but not to S2 antigen. Furthermore, a significant number of samples were positive for anti-ORF9b and anti-NSP5 antibodies. These peptides may represent good predictors for immunity and possible therapeutic targets. Overall, understanding the utility of routine serologic methods (ie, ELISA, CLIA) in the prediction of convalescence is complex. Further comprehensive studies in this area are warranted.

Discussion {#s12}
==========

Numerous immunoassays for the detection of antibodies to SARS-CoV-2 are rapidly emerging. These immunoassays have the potential to improve the diagnosis and monitoring of infection in different scenarios.^[@CIT0017],[@CIT0059]^ Published and non--peer-reviewed studies varied dramatically in the definition of patient groups, time of sample acquisition, sample size, and inclusion of relevant control sera from patients with non--SARS-CoV-2 respiratory infections. These are all critical variables that will affect the sensitivity and specificity of the different immunoassays and should be a fundamental part of the review of any validated assay.^[@CIT0015]^ Determining the final roles of LFIA and ELISA immunoassays in SARS-CoV-2 testing and research is difficult at this time, as this is limited by the pitfalls in the experimental design of many of these foundational studies. Further well-validated assays determined through studies with rigorous experimental design are needed.

In the current literature, the study methods were heterogeneous regarding the specific antigens used and the different isotypes of antibodies measured; few studies compared these variables simultaneously. The most common antigens used in the assays included RBD, S1, and NP. There was preliminary evidence that the use of particular target antigens may provide value to increase the sensitivity of antibody detection methods. However, additional comprehensive studies need to be conducted to reproduce this early reported data. In addition, antigenic epitopes within the SP appeared to be important in the immune response and thus, this region remains of interest for future detailed studies.

There is compelling evidence that using total antibody or combined IgG/IgM detection offered the highest sensitivity of detection. Data from preliminary studies indicated that additional investigations should examine the clinical correlation of different isotypes and titers to disease severity. It is also clear that the timing of sample acquisition is a crucial determinant of test accuracy, although this important information was not always clearly presented in the current literature.^[@CIT0016]^ The earliest positive results were reported by day 5 post onset of symptoms, and accuracy peaked by the second week of symptoms. Early in the course of the disease, when RT-PCR sensitivity was reported as 50% to 60%, the concomitant use of serologic tests significantly added sensitivity with consistently reported values over 90%. Moreover, after 10 to 14 days post onset of symptoms, the sensitivity of RT-PCR dropped significantly while serology testing reached its peak. As fully validated methods become commercially available, serology methods may be utilized as an adjunct tool to RT-PCR testing protocols in patients with suspected infection.

Nearly all of the current literature focused on the results obtained using serologic testing in symptomatic patients. It will be essential to define antibody responses in individuals with subclinical and mild disease before immunoassays can be used in screening and seroprevalence studies. At the time of this writing, while the potential importance of quantitative titers was raised in the literature, testing platforms available to provide this information are largely absent from clinical laboratories. Lastly, defining convalescence and the presence of long-lasting immunity to SARS-CoV-2 after infection or future vaccination is important. Additional studies are needed to determine if ease-of-use assays of antibody detection and quantitation will compare well with traditional neutralizing antibody assays. While serologic testing continues to hold promise for various applications, there are still knowledge gaps that must be clarified to give meaningful recommendations for its use in different clinical scenarios.
